Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Therapix in Oral Anti-CD3 Development Pact in China | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Therapix in Oral Anti-CD3 Development Pact in China

Will develop antibody for the treatment of a variety of inflammatory diseases

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Therapix Bio’s subsidiary, OrImmune Bio Ltd., has entered a strategic collaboration with Nanjing BioSciKin Co. to develop, manufacture and commercialize the company’s Anti-CD3 antibody in the Chinese market (China, Taiwan, Hong Kong and Macau). The Anti-CD3 antibody is an orally-administered antibody for the treatment of a variety of inflammatory diseases such as Non Alcoholic Steato Hepatitis (fatty liver disease).
 
The companies are working toward an agreement that would provide Nanjing BioSciKin with an exclusive license to OrImmune’s patents and related intellectual property for research, development, manufacture, commercialization and sublicensing, in consideration for a payment of $300,000.
 
Nanjing BioSciKin would finance the establishment of a GMP-compliant manufacturing line for the antibody. The parties will also enter into a nonexclusive supply agreement for the manufacture of the antibody for clinical trials. Nanjing BioSciKin will receive payments in connection with and/or deriving from the antibody’s commercialization.
 
Therapix Chairman Dr. Asher Shmulewitz, commented, “This agreement with Nanjing BioSciKin is an important step forward in the execution of our broader corporate strategy, which focuses on the development of novel synthetic cannabinoids and advancing our position in the emerging market for medical cannabis. We look forward to working with Nanjing BioSciKin as they advance the product toward clinical trials in Greater China, while devoting all of our internal resources to the expansion and advancement of our portfolio of cannabinoid-based product candidates.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics